Displaying 1 - 8 of 8
Metabolism, Alcohol & Toxicity
2

Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021

View
Metabolism, Alcohol & Toxicity
2

Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021

View
Viral Hepatitis
6

AbbVie: The Road to HCV Elimination: Always Forward - ILC 2021

View
Viral Hepatitis
6

AbbVie: The Road to HCV Elimination: Always Forward - ILC 2021

View
Viral Hepatitis
6

AbbVie: The Road to HCV Elimination: Always Forward - ILC 2021

View
Viral Hepatitis
6

AbbVie: The Road to HCV Elimination: Always Forward - ILC 2021

View
Viral Hepatitis
6

AbbVie: The Road to HCV Elimination: Always Forward - ILC 2021

View
Viral Hepatitis
6

AbbVie: The Road to HCV Elimination: Always Forward - ILC 2021

View